Oteseconazole
Brand Names: Vivjoa
Methodology & AI Transparency ⓘ
Oteseconazole Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Registered across 150 mg/1 Capsule under FDA code 74695-823 (manufactured/labeled by Mycovia Pharmaceuticals, Inc.), Oteseconazole delivers oral-route azole antifungal pharmacotherapy tailored to patient-specific diagnostic criteria.
- 2 Real-world patient consensus: 82% patient "Worth It" rating across 18 anonymous logs for Oteseconazole (RxNorm RXN-74695823-3238).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $69.25 cash mean against $169.66 retail pharmacy pricing.
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Oteseconazole): diarrhea (8.5%), nausea (8.4%), headache (6.6%).
Ask our AI Specialists anything about Oteseconazole
Oteseconazole Mechanism, CYP450 Pathways & DailyMed Monograph
Registered across 150 mg/1 Capsule under FDA code 74695-823 (manufactured/labeled by Mycovia Pharmaceuticals, Inc.), Oteseconazole delivers oral-route azole antifungal pharmacotherapy tailored to patient-specific diagnostic criteria.
Biochemical activity of Oteseconazole reflects azole antifungal pathway engagement after oral-route dosing (150 mg/1 Capsule, manufactured/labeled by Mycovia Pharmaceuticals, Inc., NDC 74695-823), supporting titratable maintenance pharmacotherapy.
With Biphasic clearance with 5–18 hr terminal t½ under Oteseconazole maintenance residence kinetics and Systemic oral bioavailability of roughly 67%–79% following first-pass transit bioavailability, Oteseconazole undergoes hepatic enzymatic processing and renal clearance proportional to creatinine clearance (oteseconazole) and establishes therapeutic activity over initial pharmacodynamic onset within 1–3 hrs (peak cmax) for oteseconazole.
Standard adult regimens span 150 mg/1 Capsule, Stepwise Oteseconazole titration guided by clinical response and eGFR. Prescribers screen specifically against prior anaphylaxis, angioedema, or severe hypersensitivity to oteseconazole or oteseconazole excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 oteseconazole spl, while community micro-logs most frequently note diarrhea (8.5% of reports), nausea (8.4% of reports), headache (6.6% of reports).
Avoid overlapping azole antifungal prescriptions alongside Oteseconazole to prevent cumulative receptor toxicity.
Unstandardized herbal extracts may interact pharmacodynamically with Oteseconazole maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Oteseconazole or Oteseconazole excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 Oteseconazole SPL
Logged Side-Effect Incidence (18 Reports)
Oteseconazole Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Oteseconazole)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Oteseconazole in Recurrent Vulvovaginal CONCLUSIONS: Oral oteseconazole was effective in preventing acute VVC recurrence and treating RVVC through week 48 in the CL-011 and CL-012 trials, with mostly mild TEAEs. NEJM evidence • 2022-08-15 • Phase III Randomized Trial | N = 22 | 88/100 | PMID 38319878 ↗ |
| New Insights on Phase 3 study evaluating the safety and real-world benefits of oteseconazole in: What a 219-Participant Study Found In participants with recurrent vulvovaginal candidiasis, oteseconazole was safe and efficacious in the treatment and prevention of recurrent acute vulvovaginal candidiasis episodes and was noninferior to vulvovaginal... American journal of obstetrics and gynecology • 2022-12-15 • Phase III Randomized Trial | N = 219 | 88/100 | PMID 35863457 ↗ |
| New Insights on Oteseconazole versus fluconazole for the treatment of severe vulvovaginal: What a 322-Participant Study Found No subjects discontinued study treatment or withdrew study due to side effects. Antimicrobial agents and chemotherapy • 2024-01-10 • Phase III Randomized Trial | N = 322 | 87/100 | PMID 38095426 ↗ |
Oteseconazole Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.5000/unit (~$45.00/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $169.66 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $69.25 / mo | View logs ↓ |
Oteseconazole Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Oteseconazole RxNorm Concept ID | RXN-74695823-3238 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.5000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $169.66 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $69.25 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 82.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Oteseconazole Patient Community, Cohort Filters & Dosage Logs
Deterministic Oteseconazole reference combining NIH RxNorm (RXN-74695823-3238), Medicaid NADAC ($1.5000/unit), and anonymous cohort outcomes (82% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Oteseconazole community threads and patient logs by age, biological sex, dosage, and treatment duration.